ROBOSENSE
9.2.2021 20:02:05 CET | Business Wire | Press release
RoboSense LiDAR (https://robosense.ai/ ) today released the latest version of the ground truth data system and evaluation tool chain RS-Reference 2.1, used for LiDARs and multi-sensor fusion systems performance evaluation. The original RS-Reference version was launched in the market in 2016, when the automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 project was established. Used by global OEMs and Tier1s, the system has been continuously improved and upgraded with more efficient and useful evaluation function modules and software tool chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005689/en/
While the evaluation function modules can be liked to an exam, the ground truth data is the "answer" for the evaluation of the perception system. Therefore, the accuracy of ground truth data must be significantly higher than the device under test (DuT) in all aspects including detection performance and geometric error.
The ground truth data, usually stored in the PB-Level, includes dynamic information such as obstacle types, speeds, and locations, and static information such as lane lines and road boundaries.
Data labeling quality and data generation efficiency are the key factors to ground truth data.
- The RS-Reference system provides a set of ground truth data generation and evaluation solutions, and outputs detection performance and geometric error indicators with a labeling efficiency close to 1:1. This is significantly more accurate than real-time perception, manual labeling and traditional labeling tools.
- High performance and mature sensor data collection system: the RS-Reference system contains the RoboSense 128-beam LiDAR RS-Ruby, Leopard camera, Continental 408 millimeter-wave radar, GI-6695 RTK, and two added RoboSense RS-Bpearl LiDAR for near-field blind spots in the 2.1 version.
- Detached roof-mounted deployment without vehicle body modification: the RS-Reference system adapts to different vehicle sizes, does not occupy the sensor installation position of the DuTs, and directly evaluates the intelligent driving system that is consistent with the sensor sets of commercial vehicles.
- Vastly improved/accumulated perception algorithm and offline processing mechanism: The algorithm is key to smart labeling instead of manual labeling, and is responsible for the extraction of ground truth data. The RS-Reference system uses a customized and dedicated offline perception algorithm, which is the product of RoboSense’s 13+ years’ of accumulated experience of LiDAR sensing algorithm technology. It performs a “full life process tracking and identification" for each obstacle data, and extracts all ground truth data from each frame. The RS-Reference system can pick up speed and acceleration labeling, and accurately delineate the size of the labeling frame through comprehensive shape and size information. The system is also capable of accurately dividing obstacles that are in close proximity to each other in complex scenes.
- Full-stack evaluation tool chain: it includes data collection tools, sensor calibration tools, visualization tools, manual verification tools, evaluation tools, etc. The 2.1 version upgrades the data management platform and adds the scene semantic labeling function that serves every step of the evaluation process.
- Individual sensor evaluation in the multi-sensor fusion system: not only can the RS-Reference system evaluate the result of intelligent driving's perception fusion, but it can also provide targeted solutions based on the features of different types of sensors such as LiDAR, millimeter wave radar, and camera. Dedicated or customized tool modules can be developed according to customer needs for further in-depth analysis of the performance of the sensing system.
- Extended application value of the RS-Reference: includes planning and control algorithm development support, which is able to generate massive ground truth data to build simulation scenes, and can evaluate road-side perception systems.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005689/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
